Coloplast A/S Earnings Recaps
Q3 2026
Aug 20, 2026
Shares rose 6.1% as Coloplast reassured investors with sustained leadership positions, a strong product portfolio, and clear strategic priorities to drive growth, particularly emphasizing growth potential in the U.S. market.
Key takeaways
- Chronic Care remains the core segment, representing over 75% of sales, with continued leadership and an annuity-based business model reinforcing revenue stability.
- U.S. market highlighted as a significant growth opportunity, currently under-penetrated with market shares of 15-20% in Ostomy Care and about 30% in Continence Care.
- Biologics segment in Wound & Tissue Repair faces challenges due to a recent U.S. market reset but focusing on inpatient care and clinical differentiation to restore profitable growth.
- New CEO Gavin Wood is prioritizing disciplined capital allocation, investment governance, and innovation pipeline to accelerate growth and extend competitive moats.
- Leadership changes include appointing a new Chief People Officer and executive realignment in Wound & Tissue Repair to strengthen organizational focus and execution.